/ PORTFOLIO
WUGEN-Logo-White-Background-FIN-1024x360

St. Louis, MO

Wugen is developing a novel chimeric antigen receptor (CAR-T) therapy platform for T-cell malignancies. Wugen’s state-of-the-art gene editing and CAR-T cell technology enable “off-the-shelf” therapies that would avoid rejection by the recipient. Wugen was co-founded by RiverVest based on technology licensed from Washington University in St. Louis.

logo-rivervest

© Copyright RiverVest® All Rights Reserved.